GENELINK ANNOUNCES PUBLICATION OF ITS PATENT APPLICATION RELATING TO METHODS OF ASSESSING SKIN HEALTH
June 4, 2003

MARGATE, NJ - (Business Wire) - June 4, 2003 - GeneLink BioSciences, Inc. (GNLK:BB) announced today that on April 17, 2003, the U.S. Patent & Trademark Office formally published the second of GeneLink's patent applications relating to methods of assessing oxidative stress for skin health by analyzing genetic polymorphisms. Filed on September 20, 2002, U.S. Patent Application No. 10/247,935 can be reviewed at the following World Wide Web URL:
http://appft1.uspto.gov/netahtml/PTO/srchnum.html and entering the number: 20030073612

GeneLink's proprietary test for the assessment of oxidative stress genes is used to genetically predict an individual's risk for skin aging. It has a significant application in the skincare industry. The use of antioxidant genetic information is a remarkable tool to combat skin aging as it can help individuals improve their skin condition and achieve younger looking skin.

GeneLink's genetic assessments for customized skin care and vitamins were featured on ABC's The View on May 5, 2003. A summary of the Show's segment can reviewed at
http://abc.abcnews.go.com/daytime/theview/episodes/2003/20030505.html

GeneLink is licensing these proprietary assessments to companies that manufacture or market to the $100 Billion plus personal care, nutritional supplement and skin care industries. These profile assessments are tools to help companies create and deliver more effective products - personalized wellness and "quality of life" products tailored to their customer's individual needs - based on the science of genetics. Consumers will no longer be forced to guess what nutritional supplements or skin care products are best for their specific needs.

For the first time, simply by swabbing the inside of the mouth with GeneLink's patented DNA Collection Kit®, consumers can now enjoy the benefits of a tailored nutritional or skin care regimen designed to their individual needs. For more information about GeneLink, visit its website at www.genelink.info.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.